Hybrid Event
19-21 May 2026Steigenberger Icon Wiltcher's, Brussels, BEHybrid Event
19-21 May 2026,
Steigenberger Icon Wiltcher's, Brussels, BE
19-21 May 2026,
Steigenberger Icon Wiltcher's, Brussels, BE
Wednesday 20 May 2026
Stay ahead of regulatory changes with expert insights on the evolving General Pharmaceutical Legislation and the wide-reaching impact of Most-Favoured-Nations (MFN) clauses. Gain actionable guidance from the EU Commission, EMA, and top pharma leaders to navigate today’s complex and dynamic landscape with confidence
Regulatory Frameworks | What's On?
Regulatory Exclusivity in the EU Pharmaceutical Legislation
- EMA restructuring and innovation policies
- Regulatory data protection and market exclusivity
- Impact of the obligation to launch and supply
- Imposed label changes and potential repercussions
Navigating Geopolitical and Industry Shifts
- Key insights into the EU Commission’s perspective on European competitiveness
- The implications of US manufacturing policies on critical medicines
- Repercussions of US policy on pricing and reimbursement
- How can manufacturers balancing the EU Life Science Strategy with US policies?
New Legal Developments and Market Access
- How will the Biotech Act simplify clinical trials and unlock funding mechanisms?
- HTA Regulation: aligning market access, pricing, and reimbursement strategies
- Critical Medicines Act: new obligations for launch, supply, and notifications
- Latest on streamlining EU MDR, IVDR, and AI Act for industry efficiency
Discover What Else is on the Agenda for 2026!
